Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Why Opendoor Technologies Stock Popped Today (Fool) +++ OPENDOOR Aktie -3,33%

AVALO THERAPEUTICS Aktie

 >Aktienkurs 
4.185 EUR    +0.1%    (Tradegate)
Ask: 4.305 EUR / 100 Stück
Bid: 4.11 EUR / 100 Stück
Tagesumsatz: 20 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -0,2%
1 Monat: -1,6%
3 Monate: +1,7%
6 Monate: -35,6%
1 Jahr: -62,6%
laufendes Jahr: -47,7%
>AVALO THERAPEUTICS Aktie
Name:  AVALO THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US05338F3064 / A3E2FR
Symbol/ Ticker:  C6K0 (Frankfurt) / AVTX (NASDAQ)
Kürzel:  FRA:C6K0, ETR:C6K0, C6K0:GR, NASDAQ:AVTX
Index:  -
Webseite:  https://www.avalotx.com/
Marktkapitalisierung:  45.91 Mio. EUR
Umsatz:  0.38 Mio. EUR
EBITDA:  -43.41 Mio. EUR
Gewinn je Aktie:  89.686 EUR
Schulden:  0.69 Mio. EUR
Liquide Mittel:  108.48 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  0.04 / -
KUV/ KBV/ PEG:  100.09 / 0.39 / -
Gewinnm./ Eigenkapitalr.:  16% / 678.24%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  AVALO THERAPEUTICS, AVALO THERAPEUTIC
Letzte Datenerhebung:  16.07.25
>Eigentümer
Aktien: 10.83 Mio. St.
f.h. Aktien: 3.68 Mio. St.
Insider Eigner: 6.39%
Instit. Eigner: 76.24%
>Peer Group

 
23.06.25 - 13:03
 Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
 
WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences:...
18.06.25 - 13:03
 Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors (GlobeNewswire EN)
 
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors....
27.05.25 - 16:09
 Avalo Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June....
12.05.25 - 13:24
 Avalo Therapeutics GAAP EPS of -$1.25 misses by $0.20 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.05.25 - 13:03
 Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire EN)
 
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025....
30.04.25 - 13:03
 Avalo Therapeutics to Participate in The Citizens Life Sciences Conference (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET....
26.03.25 - 12:15
 Avalo Therapeutics names Michael Heffernan as chair (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
26.03.25 - 12:03
 Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company....
25.03.25 - 20:48
 Avalo Therapeutics €Represents An Attractive Pure-Play,€ Analyst Initiates Coverage With Over 300% Stock Upside (Benzinga)
 
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target. Latest Ratings for AVTX DateFirmActionFromTo Mar 2022JefferiesDowngradesBuyHold Mar 2022RBC CapitalMaintainsOutperform Sep 2021RBC CapitalInitiates Coverage OnOutperform View More Analyst Ratings for AVTX View the Latest Analyst Ratings read more...
20.03.25 - 12:24
 Avalo Therapeutics GAAP EPS of -$20.91, revenue of $0.44M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.03.25 - 12:03
 Avalo Reports 2024 Financial Results and Recent Business Updates (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024....
04.02.25 - 14:03
 Avalo Therapeutics to Present at Oppenheimer′s 35th Annual Healthcare Life Sciences Conference (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET....
02.01.25 - 13:03
 Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization....
15.11.24 - 01:02
 Insiderhandel: Aufsichtsrat kauft Aktien von Avalo Therapeutics im Wert von 6250 USD (Insiderkauf)
 
Almenoff, June Sherie - Aufsichtsrat - Tag der Transaktion: 2024-11-12...
15.11.24 - 01:02
 Insiderhandel: Aufsichtsrat kauft Aktien von Avalo Therapeutics im Wert von 6500 USD (Insiderkauf)
 
Almenoff, June Sherie - Aufsichtsrat - Tag der Transaktion: 2024-11-13...
12.11.24 - 15:12
 Avalo Therapeutics receives $69.4M in proceeds from full exercise of private placement warrants (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
12.11.24 - 13:06
 Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement....
11.11.24 - 13:03
 Avalo Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences:...
07.11.24 - 13:03
 Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the third quarter of 2024....
08.10.24 - 13:06
 Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa (GlobeNewswire EN)
 
WAYNE, Pa. and ROCKVILLE, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that the first patient has been dosed in the Company's Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Malern und Dichtern war es stets gleichermaßen erlaubt zu sagen, was auch immer ihnen beliebt. - Quintus Flaccus Horaz
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!